How to avoid inappropriate therapy

Current Opinion in Cardiology

Volumn 23, Issue 1, 2008, Pages 65-71

  Israel, Carsten W ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Enhanced detection criteria; Implantable cardioverter defibrillator; Inappropriate therapy; Supraventricular tachycardia; Ventricular tachycardia

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DILTIAZEM; SOTALOL; VERAPAMIL;

CATHETER ABLATION; CLINICAL TRIAL; CONVULSIVE THERAPY; DEFIBRILLATOR; ELECTROMAGNETIC FIELD; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE TACHYCARDIA; HUMAN; PRIORITY JOURNAL; REVIEW; SINUS TACHYCARDIA; SUPRAVENTRICULAR TACHYCARDIA;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CATHETER ABLATION; DEFIBRILLATORS, IMPLANTABLE; ELECTROMAGNETIC FIELDS; HUMANS; QUALITY OF HEALTH CARE; TACHYCARDIA, VENTRICULAR;

EID: 40349083845     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282f30436     Document Type: Review

References (68)

1. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101:1297-1302.
2. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337:1576-1584.
3. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102:748-754.
4. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-883.
5. Bardy GH, Lee KL, Mark DB, et al., Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237.
6. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-2150.
7. Sarkozy A, Boussy T, Kourgiannides G, et al. Long-term follow-up of primary prophylactic implantable cardioverter- defibrillator therapy in Brugada syndrome. Eur Heart J 2007; 28:334-344. This describes an interesting new study on clinical results in Brugada syndrome with long-term data collection from a large variety of hospitals.
8. Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation 2006; 114:2317-2324. The authors present a highly important new analysis of ICD therapy in Brugada syndrome showing that inappropriate therapy plays an important role in these typically young and physically active patients
9. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298:405-412. This is a new long-term follow-up of one of the biggest groups of patients with hypertrophic cardiomyopathy.
10. Daubert JP, Zareba W, Rosero SZ, et al. Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome. Am Heart J 2007; 153 (suppl):53-58.
11. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachycardia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovascular Electrophysiol 2004; 15:1002-1009.
12. Gehi AK, Mehta D, Gomes JA. Evaluation and management of patients after implantable cardioverter-defibrillator shock. JAMA 2006; 296:2839-2847. This is a very comprehensive review on the management of patients with an ICD, aiming predominantly at nonelectrophysiologists who also treat the growing number of ICD recipients
13. Francis J, Johnson B, Niehaus M. Quality of life in patients with implantable cardioverter defibrillators. Indian Pacing Electrophysiol J 2006; 6:173-181.
14. Sears SF, Sowell LD, Kuhl EA, et al. The ICD shock and stress management program: a randomized trial of psychosocial treatment to optimize quality of life in ICD patients. Pacing Clin Electrophysiol 2007; 30:858-864.
15. Messali A, Thomas O, Chauvin M, et al. Death due to an implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 2004; 15:953-956.
16. Sweeney MO, Wathen MS, Volosin K, et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 2005; 111:2898-2905.
17. Friedman PA, McClelland RL, Bamlet WR, et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation 2006; 113:2871-2879. This interesting new study demonstrated an improved ventricular tachycardia/SVT discrimination in well programmed dual-chamber ICDs.
18. Kim MH, Bruckman D, Sticherling C, et al. Diagnostic value of single versus dual chamber electrograms recorded from an implantable defibrillator. J Intervent Card Electrophysiol 2003; 9:49-53.
19. Stuber T, Eigenmann C, Delacrétaz E. Inappropriate interventions during the long-term follow-up of patients with an implantable defibrillator. Swiss Med Wkly 2007; 137:228-233.
20. Dorian P, Philippon F, Thibault B, et al. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm 2004; 1:540-547.
21. Bänsch D, Steffgen F, Grönefeld G, et al. The 1&1 trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation 2004; 110:1022-1029.
22. Wilkoff BL, Kuhlkamp V, Volosin K, et al. Critical analysis of dual-chamber implantable cardioverter-defibrillator arrhythmia detection: results and technical considerations. Circulation 2001; 103:381-386.
23. Hammill SC, Friedman PA. Shocking sinus: how inappropriate! J Cardiovasc Electrophysiol 2000; 11:1116-1118.
24. Nanthakumar K, Paquette M, Newman D, et al. Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators. Am Heart J 2000; 139:797-803.
25. Grimm W, Flores BT, Marchlinski FE. Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy. Circulation 1993; 87:1880-1888.
26. Fogoros RN, Elson JJ, Bonnet CA. Actuarial incidence and pattern of occurrence of shocks following implantation of the automatic implantable cardioverter defibrillator. Pacing Clin Electrophysiol 1989; 12:1465-1473.
27. Neuzner J, Pitschner HF, Schlepper M. Programmable VT detection enhancements in implantable cardioverter defibrillator therapy. Pacing Clin Electrophysiol 1995; 18:539-547.
28. Garcia-Alberola A, Yli-Mayry S, Block M, et al. RR interval variability in irregular monomorphic ventricular tachycardia and atrial fibrillation. Circulation 1996; 93:295-300.
29. Arenal A, Ortiz M, Peinado R, et al. Differentiation of ventricular and supraventricular tachycardias based on the analysis of the first postpacing interval after sequential antitachycardia pacing in implantable cardioverter-defibrillator patients. Heart Rhythm 2007; 4:316-322.
30. Kuhlkamp V, Dornberger V, Mewis C, et al. Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing. J Cardiovasc Electrophysiol 1999; 10:905-915.
31. Deisenhofer I, Kolb C, Ndrepepa G, et al. Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study. J Cardiovasc Electrophysiol 2001; 12:134-142.
32. Theuns DA, Klootwijk AP, Goedhart DM, Jordaens LJ. Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. J Am Coll Cardiol 2004; 44:2362-2367.
33. Israel CW, Grönefeld G, Iscolo N, et al. Discrimination between ventricular and supraventricular tachycardia by dual chamber cardioverter defibrillators: importance of the atrial sensing function. Pacing Clin Electrophysiol 2001; 24:183-190.
34. Hintringer F, Schwarzacher S, Eibl G, Pachinger O. Inappropriate detection of supraventricular arrhythmias by implantable dual chamber defibrillators: a comparison of four different algorithms. Pacing Clin Electrophysiol 2001; 24:835-841.
35. Soundarraj D, Thakur RK, Gardiner JC, et al. Inappropriate ICD therapy: does device configuration make a difference? Pacing Clin Electrophysiol 2006; 29:810-815.
36. Theuns DA, Rivero-Ayerza M, Boersma E, Jordaens L. Prevention of inappropriate therapy in implantable defibrillators: a meta-analysis of clinical trials comparing single-chamber and dual-chamber arrhythmia discrimination algorithms. Int J Cardiol 2007; 17 April [Epub ahead of print].
37. Klingenheben T, Sticherling C, Skupin M, Hohnloser SH. Intracardiac QRS electrogram width. An arrhythmia detection feature for implantable cardioverter defibrillators: exercise induced variation as a base for device programming. Pacing Clin Electrophysiol 1998; 21:1609-1617.
38. Sinha AM, Stellbrink C, Schuchert A, et al. Clinical experience with a new detection algorithm for differentiation of supraventricular from ventricular tachycardia in a dual-chamber defibrillator. J Cardiovasc Electrophysiol 2004; 15:646-652.
39. Theuns DA, Rivero-Ayerza M, Goedhart DM, et al. Evaluation of morphology discrimination for ventricular tachycardia diagnosis in implantable cardioverter-defibrillators. Heart Rhythm 2006; 3:1332-1338.
40. Klein GJ, Gillberg JM, Tang A, et al. Improving SVT discrimination in singlechamber ICDs: a new electrogram morphology-based algorithm. J Cardiovasc Electrophysiol 2006; 17:1310-1319.
41. Corbisiero R, Lee MA, Nabert DR, et al. Performance of a new single-chamber ICD algorithm: discrimination of supraventricular and ventricular tachycardia based on vector timing and correlation. Europace 2006; 8:1057-1061.
42. Gold MR, Shorofsky SR, Thompson JA, et al. Advanced rhythm discrimination for implantable cardioverter defibrillators using electrogram vector timing and correlation. J Cardiovasc Electrophysiol 2002; 13:1092-1097.
43. Berger RD, Lerew DR, Smith JM, et al. The Rhythm ID Going Head to Head Trial (RIGHT): design of a randomized trial comparing competitive rhythm discrimination algorithms in implantable cardioverter defibrillators. J Cardiovasc Electrophysiol 2006; 17:749-753.
44. Alter P, Waldhans S, Plachta E, et al. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol 2005; 28:926-932.
45. Candinas R, Kramm B, Buckingham T. Inappropriate implantable cardioverter defibrillator shocks due to ventricular extrasystoles despite use of a reconfirmation algorithm. Eur J Card Pacing Electrophysiol 1996; 6:47-50.
46. Goldberger JJ, Horvath G, Challapalli R, Kadish AH. Inappropriate implantable cardioverter-defibrillator therapy due to the detection of premature ventricular complexes. Pacing Clin Electrophysiol 1999; 22:825-828.
47. Wolpert C, Jung W, Spehl S, et al. Inappropriate discharge of an implantable cardioverter-defibrillator caused by the combined count criterion. J Interv Cardiol Electrophysiol 1998; 2:53-56.
48. Mansour F, Thibault B, Dubuc M, et al. Shocking truths about implantable cardioverter defibrillator monitoring zones. Pacing Clin Electrophysiol 2007; 30:1146-1148.
49. Moore DR, Kok LC, Vijayaraman P. Apparent inappropriate shocks from an implantable cardioverter defibrillator: What is the mechanism? J Cardiovasc Electrophysiol 2004; 15:116-117.
50. Anderson MH, Murgatroyd FD, Hnatkova K, et al. Performance of basic ventricular tachycardia algorithms in implantable cardioverter defibrillators: Implications for device programming. Pacing Clin Electrophysiol 1997; 20:2975-2983.
51. Gunderson BD, Abeyratne AI, Olson WH, Swerdlow CD. Effect of programmed number of intervals to detect ventricular fibrillation on implantable cardioverter-defibrillator aborted and unnecessary shocks. Pacing Clin Electrophysiol 2007; 30:157-165. The study demonstrated an important lesson: ventricular tachycardia detection can easily be prolonged to 18 cycles with only a theoretical delay of 1-2 s of ventricular tachycardia detection while a significant number of inappropriate or unnecessary therapies can be prevented.
52. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. J Am Med Ass 2006; 295:165-171. An important trial demonstrated a significantly lower incidence of appropriate and inappropriate ICD therapy if sotalol or amiodarone are given in ICD patients
53. Bänsch D, Oyang F, Antz M, et al. Successful catheter ablation of electrical storm after myocardial infarction. Circulation 2003; 108:3011-3016.
54. Weretka S, Michaelsen J, Becker R, et al. Ventricular oversensing: a study of 101 patients implanted with dual chamber defibrillators and two different lead systems. Pacing Clin Electrophysiol 2003; 26:65-70.
55. Woo A, Monakier D, Harris L, et al. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart 2007; 93:1044-1045.
56. Begley DA, Mohiddin SA, Tripodi D, et al. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003; 26:1887-1896.
57. Watanabe H, Chinushi M, Izumi D, et al. Decrease in amplitude of intracardiac ventricular electrogram and inappropriate therapy in patients with an implantable cardioverter defibrillator. Int Heart J 2006; 47:363-370. This provides important analysis and comprehensive explanation of R wave sensing as the most important predictor of inappropriate T wave oversensing
58. Hsu SS, Mohib S, Schroeder A, Deger FT. T wave oversensing in implantable cardioverter defibrillators. J Interv Card Electrophysiol 2004; 11:67-72.
59. Wieczorek M, Hoeltgen R, Djajadisastra I. Avoidance of intermittent T-wave oversensing with device programming. Herzschrittmacherther Elektrophysiol 2006; 17:106-111.
60. Alasti M, Haghjoo M, Alizadeh A, et al. Inappropriate therapy due to triple counting of the ventricular electrogram in a patient with implantable cardioverter-defibrillator. Heart Rhythm 2005; 2:1253-1255.
61. Boriani G, Biffi M, Frabetti L, et al. Cardioverter-defibrillator oversensing due to double counting of ventricular tachycardia electrograms. Int J Cardiol 1998; 66:91-95.
62. Barold SS, Herweg B, Gallardo I. Double counting of the ventricular electrogram in biventricular pacemakers and ICDs. Pacing Clin Electrophysiol 2003; 26:1645-1648.
63. Hauser RG, Kallinen LM, Almquist AK, et al. Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm 2007; 4:892-896.
64. Pinski S, Trohman RG. Interference in implantable cardiac devices, part I. Pacing Clin Electrophysiol 2002; 25:1367-1381.
65. Groh WJ, Boschee SA, Engelstein ED, et al. Interactions between electronic article surveillance systems and implantable cardioverter- defibrillators. Circulation 1999; 100:387-392.
66. Rickli H, Facchini M, Brunner H, et al. Induction ovens and electromagnetic interference: what is the risk for patients with implanted pacemakers? Pacing Clin Electrophysiol 2003; 26:1494-1497.
67. Kolb C, Zrenner B, Schmitt C. Incidence of electromagnetic interference in implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2001; 24:465-468.
68. Wathen M. Implantable cardioverter defibrillator shock reduction using new antitachycardia pacing therapies. Am Heart J 2007; 153 (Suppl):44-52. Analysis from the PainFREE II trial demonstrating the reduction in shock therapy if ATP is programmed for a wide range of VT rates